A Study of MLN9708 in Japanese Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Status:
Terminated
Trial end date:
2019-02-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK) of
ixazomib alone or in combination with lenalidomide and dexamethasone (Rd), and antitumor
activity of ixazomib in participants with RRMM.